Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors
| Autor: | Louis P. Sandjo, Morgana Moretti, Rui Daniel Prediger, Anicleto Poli, Dirleise Colle, Ana Lúcia S. Rodrigues, Marcelo Farina, Danúbia Bonfanti dos Santos, Andréia S. Cunha, Mauricio P. Cunha, Filipe C. Matheus, Tuane Bazanella Sampaio, Carlos H. Blum-Silva, Flávio Henrique Reginatto |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Male Dopamine and cAMP-Regulated Phosphoprotein 32 Dyskinesia Drug-Induced Reserpine Agmatine Tyrosine 3-Monooxygenase Dopamine Pharmacology Nitric Oxide Receptors N-Methyl-D-Aspartate Receptors Dopamine 03 medical and health sciences Behavioral Neuroscience chemistry.chemical_compound Mice 0302 clinical medicine Dopamine receptor D2 medicine Animals Cerebral Cortex Dopamine Plasma Membrane Transport Proteins Dyskinesias Chemistry Dopaminergic Glutamate receptor Corpus Striatum Vesicular monoamine transporter Disease Models Animal Oxidative Stress 030104 developmental biology Dyskinesia medicine.symptom Dizocilpine Maleate Nitric Oxide Synthase Excitatory Amino Acid Antagonists 030217 neurology & neurosurgery Locomotion medicine.drug |
| Zdroj: | Behavioural brain research. 312 |
| ISSN: | 1872-7549 |
| Popis: | Dyskinesia consists in a series of trunk, limbs and orofacial involuntary movements that can be observed following long-term pharmacological treatment in some psychotic and neurological disorders such as schizophrenia and Parkinson's disease, respectively. Agmatine is an endogenous arginine metabolite that emerges as neuromodulator and a promising agent to manage diverse central nervous system disorders by modulating nitric oxide (NO) pathway, glutamate NMDA receptors and oxidative stress. Herein, we investigated the effects of a single intraperitoneal (i.p.) administration of different agmatine doses (10, 30 or 100mg/kg) against the orofacial dyskinesia induced by reserpine (1mg/kg,s.c.) in mice by measuring the vacuous chewing movements and tongue protusion frequencies, and the duration of facial twitching. The results showed an orofacial antidyskinetic effect of agmatine (30mg/kg, i.p.) or the combined administration of sub-effective doses of agmatine (10mg/kg, i.p.) with the NMDA receptor antagonists amantadine (1mg/kg, i.p.) and MK801 (0.01mg/kg, i.p.) or the neuronal nitric oxide synthase (NOS) inhibitor 7-nitroindazole (7-NI; 0.1mg/kg, i.p.). Reserpine-treated mice displayed locomotor activity deficits in the open field and agmatine had no effect on this response. Reserpine increased nitrite and nitrate levels in cerebral cortex, but agmatine did not reverse it. Remarkably, agmatine reversed the decrease of dopamine and non-protein thiols (NPSH) levels caused by reserpine in the striatum. However, no changes were observed in striatal immunocontent of proteins related to the dopaminergic system including tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter type 2, pDARPP-32[Thr75], dopamine D1 and D2 receptors. These results indicate that the blockade of NO pathway, NMDAR and oxidative stress are possible mechanisms associated with the protective effects of agmatine against the orofacial dyskinesia induced by reserpine in mice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect